Citation

Wilkowska A, Szałach, Cubała WJ. Neuropsychiatr. Dis. Treat. 2020; 16: 2707-2717.

Copyright

(Copyright © 2020, Dove Press)

DOI

10.2147/NDT.S282208

PMID

unavailable

Abstract

Bipolar disorder (BD) is a psychiatric illness associated with high morbidity, mortality and suicide rate. It has neuroprogressive course and a high rate of treatment resistance. Hence, there is an unquestionable need for new BD treatment strategies. Ketamine appears to have rapid antidepressive and antisuicidal effects. Since most of the available studies concern unipolar depression, here we present a novel insight arguing that ketamine might be a promising treatment for bipolar disorder. © 2020 Wilkowska et al.

Language: en

Keywords

human; Review; quality of life; bipolar disorder; Bipolar disorder; ketamine; suicidal ideation; lithium; risk assessment; treatment outcome; bipolar depression; Ketamine; mental performance; treatment planning; signal transduction; nonhuman; placebo; drug efficacy; enzyme inhibition; dose response; low drug dose; remission; Treatment resistance; interleukin 6; body mass; interleukin 1beta; n methyl dextro aspartic acid receptor; brain derived neurotrophic factor; clinical effectiveness; treatment duration; interleukin 10; nerve cell plasticity; epigenetics; intestine flora; cytokine release; synaptogenesis; neuromodulation; Staging; treatment resistant depression; esketamine; glycogen synthase kinase 3; Neuroprogression